REFERENCES
- British HIV Association (BHIVA) guidelines for the treat-ment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2(4):276–313.
- Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5,2001. HIV Clin Trials. 2001;2(3):227–306.
- Staszewski S. Update on Study 006-EFV + AZT + 3TC versus the current "standard of care" IDV + AZT + 3TC. Int J Clin PracL 1999;103(suppl):10–15.
- Staszewski S, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N EngIJ Med. 1999;341(25):1865–1873.
- Katalama CM, Johnson R, Squires V, et al. The Atlantic Study: a randomised open-label study comparing two pro-tease inhibitors (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen. Paper presented at: Sixth Conference on Retroviruses and Opportunistic Infections; 1999; Chicago, IL.
- Sulkowski MS, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182–189.
- Fellay J, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lan-cet. 2001;358(9290):1322–1327.
- Clarke S, et al. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis. 2000;31(3):806–807.
- Delaugerre C, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med ViroL 2001;65(3):445–448.
- Miller V, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor lovirideTM. Antimicrob Agents Chemother. 1998;42(12):3123–3129.
- Phillips AN, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS. 200115(18):2385–2395.
- Matthews GV, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive pa-tients: a cohort study. AIDS. 2002;16(1):53–61.
- Byar DP. Why data bases should not replace randomized clinical trials. Biometrics. 1980;36(2):337–342.
- Sacks H, Chalmers TC, Smith H Jr. Randomized vs historic controls for clinical trials. Am J Med. 1982;72:233–240.
- Phillips AN, et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS. 1999;13(15):2075–2082.
- Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–1892.
- Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886.